Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1570
+0.0090 (6.08%)
At close: Oct 9, 2026
Northwest Biotherapeutics Employees
Northwest Biotherapeutics had 105 employees as of December 31, 2025. The number of employees increased by 80 or 320.00% compared to the previous year. That makes Northwest Biotherapeutics the 31,122nd largest employer in the world and 3,981st in the United States.
Employees
105
Change (1Y)
80
Growth (1Y)
320.00%
Revenue / Employee
$20,695
Profits / Employee
-$370,314
Market Cap
267.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 105 | 80 | 320.00% | 105 | 0 |
| Dec 31, 2024 | 25 | 0 | - | 25 | 0 |
| Dec 31, 2023 | 25 | 3 | 13.64% | 25 | 0 |
| Dec 31, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Dec 31, 2021 | 19 | 0 | - | 19 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 142 |
| Silence Therapeutics | 88 |
| Vaxart | 65 |
| CytoDyn | 14 |
| Nuo Therapeutics | 10 |
Northwest Biotherapeutics News
- 2 days ago - Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production - PRNewsWire
- 4 days ago - Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference - PRNewsWire
- 2 months ago - Northwest Biotherapeutics enters MOU for collaboration with SPIMACO - TheFly
- 2 months ago - Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company - PRNewsWire
- 3 months ago - Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses - PRNewsWire
- 3 months ago - Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting - PRNewsWire
- 5 months ago - Northwest Biotherapeutics names Annalisa Jenkins as strategic advisor - TheFly
- 5 months ago - Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform - PRNewsWire